title: Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice.
abstract: OBJECTIVE
  The anti-anginal efficacy of the selective I(f) inhibitor ivabradine has been demonstrated in controlled clinical trials. However, there is limited information about the safety and efficacy of a combined treatment of ivabradine with beta-blockers, particularly outside of clinical trials in every day practice. This analysis from the REDUCTION study evaluated the safety and efficacy of a combined therapy of beta-blockers and ivabradine in every day practice.
  
  
  METHODS
  In this multi-center study 4,954 patients with stable angina pectoris were treated with ivabradine in every day routine practice and underwent a clinical follow-up for 4 months. 344 of these patients received a co-medication with beta-blockers. Heart rate (HR), angina pectoris episodes, nitrate consumption, overall efficacy and tolerance were analyzed.
  
  
  RESULTS
  After 4 months of treatment with ivabradine HR was reduced by 12.4 ± 11.6 bpm from 84.3 ± 14.6 to 72.0 ± 9.9 bpm, p < 0.0001. Angina pectoris episodes were reduced from 2.8 ± 3.3 to 0.5 ± 1.3 per week, p < 0.0001. Consumption of short-acting nitrates was reduced from 3.7 ± 5.6 to 0.7 ± 1.7 units per week, p < 0.0001. Five patients (1.5%) reported adverse drug reactions (ADR). The most common ADR were nausea and dizziness (<0.6% each). There was no clinically relevant bradycardia. Efficacy and tolerance were graded as 'very good/good' for 96 and 99% of the patients treated.
  
  
  CONCLUSIONS
  Ivabradine effectively reduces heart rate and angina pectoris in combination with beta-blockers and is well tolerated by patients in every day practice.
authors.affiliation: Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Germany. rkoester@uke.uni-hamburg.de
authors.forename: Ralf
authors.initials: R
authors.lastname: Koester
authors.forename: Jan
authors.initials: J
authors.lastname: Kaehler
authors.forename: Henning
authors.initials: H
authors.lastname: Ebelt
authors.forename: Gerold
authors.initials: G
authors.lastname: Soeffker
authors.forename: Karl
authors.initials: K
authors.lastname: Werdan
authors.forename: Thomas
authors.initials: T
authors.lastname: Meinertz
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001552:Benzazepines / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077550:Ivabradine; D008297:Male; D049990:Membrane Transport Modulators / Q000627:therapeutic use*; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D001552:Benzazepines; D049990:Membrane Transport Modulators; D000077550:Ivabradine
references.citation: Eur Heart J. 2006 May;27(10):1153-8
references.pmid: 16399775
references.citation: Pharmacol Res. 2006 May;53(5):399-406
references.pmid: 16638640
references.citation: Clin Res Cardiol. 2008 Aug;97(8):513-47
references.pmid: 18726642
references.citation: Am J Cardiol. 2008 Dec 1;102(11):1524-9
references.pmid: 19026308
references.citation: N Engl J Med. 2000 Jun 22;342(25):1907-9
references.pmid: 10861329
references.citation: Eur Heart J. 2006 Jun;27(11):1341-81
references.pmid: 16735367
references.citation: Eur Heart J. 2005 Dec;26(23):2529-36
references.pmid: 16214830
references.citation: N Engl J Med. 2000 Jun 22;342(25):1887-92
references.pmid: 10861325
references.citation: Circulation. 1967 Jun;35(6):1073-83
references.pmid: 6026199
references.citation: Drugs. 2007;67 Suppl 2:3-13
references.pmid: 17999559
references.citation: J Am Coll Cardiol. 2007 Aug 28;50(9):823-30
references.pmid: 17719466
references.citation: Sci Am. 1977 Oct;237(4):132-40
references.pmid: 905817
references.citation: Circulation. 2007 Dec 4;116(23):2762-72
references.pmid: 17998462
references.citation: Drugs. 2007;67 Suppl 2:35-41
references.pmid: 17999562
references.citation: Am Heart J. 1987 Jun;113(6):1489-94
references.pmid: 3591616
references.citation: Clin Res Cardiol. 2009 Oct;98(10):681-4
references.pmid: 19711110
references.citation: Circulation. 1976 Sep;54(3):522-3
references.pmid: 947585
references.citation: Eur Heart J. 2009 Oct;30(19):2337-45
references.pmid: 19720635
references.citation: Clin Res Cardiol. 2009 Oct;98(10):665-76
references.pmid: 19693626
references.citation: Am J Med. 2004 Aug 15;117(4):234-41
references.pmid: 15308432
references.citation: Circulation. 1991 Apr;83(4):1263-70
references.pmid: 1901527
references.citation: Clin Res Cardiol. 2008 Nov;97(11):811-9
references.pmid: 18648727
references.citation: Lancet. 2008 Sep 6;372(9641):807-16
references.pmid: 18757088
references.citation: Eur Heart J. 2009 Mar;30(5):540-8
references.pmid: 19136486
references.citation: Circulation. 2003 Feb 18;107(6):817-23
references.pmid: 12591750
references.citation: Drugs. 2004;64(16):1757-65
references.pmid: 15301560
references.citation: Clin Res Cardiol. 2009 Aug;98(8):513-5
references.pmid: 19547907
references.citation: Am Heart J. 2009 Oct;158(4):e51-7
references.pmid: 19781403
references.citation: Lancet. 2008 Sep 6;372(9641):817-21
references.pmid: 18757091